Conference Call with Hester Biosciences Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q4FY25 results Revenue from operations: Rs 819.25 million compared to Rs 792.55 million during Q4FY24, change 3%. Gross Profit Margin: Rs 611.83 million compared to Rs 577.16 million during Q4FY24, change 6%. EBITDA: Rs 135.41 million compared to Rs 205.48 million during Q4FY24, change -34%. EBITDA margin: 17% for Q4FY25. PAT: Rs 15.41 million compared to Rs 63.95 million during Q4FY24, change -76%. PAT margin: 2% for Q4FY25. Result PDF